Company news: Sanofi and Valent

Share this article:
Sanofi will sell its Dermik skincare unit to Valeant Pharmaceuticals for $425 million. The deal includes Dermik's aesthetic and therapeutic business in the US and Canada along with a global aesthetic business with sales of $206 million in 2010, along with Sanofi's Laval, Canada site, including Dermik's manufacturing facility. Dermik brands include BenzaClin for acne, Carac for keratoses and Sculptra, a facial injectable for facial wrinkles and folds.

PhRMA took aim at proposed cuts to Medicare Part D under discussion in debt ceiling negotiations, estimating that a $20 billion per year reduction in biopharmaceutical industry revenue would cost the country 260,000 jobs. “The President and some in Congress have proposed including government-mandated rebates in Medicare Part D as part of a debt ceiling agreement,” said PhRMA chief John Castellani in a statement. “Such a provision would have a dramatic negative effect on the economy and patients, and could undermine the success of the Part D program, which has very high beneficiary satisfaction and has cost far less than original government projections.”  

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions